Article info
PDFExtended report
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
- Correspondence to:
Dr Ronald F van Vollenhoven
Department of Rheumatology, Karolinska Hospital, D2-1, 17176 Stockholm, Sweden; ronald.vanvollenhovenks.se
Citation
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
Publication history
- Accepted June 29, 2003
- First published February 27, 2004.
Online issue publication
March 12, 2004
Article Versions
- Previous version (27 February 2004).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2004 by Annals of the Rheumatic Diseases